DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Fukuoka M, Wu YL, Thongprasert S et al.
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
J Clin Oncol 2011;
29: 2866-2874
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.